pdgf
Recombinant proteinexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
1
Phase 4
1
Earliest trial started Mar 1, 2017 (NCT02996760)
Timeline
Indications
Mechanism of action
- Platelet-derived growth factor subunit ASupplementation
PDGFA supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pdgf
- pdgf
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06634030 | Phase 2 | Nov 30, 2024 | Lynch Regenerative Medicine, LLC, Vanderbilt University |
| NCT06632418 | Phase 2 | Oct 31, 2024 | Lynch Regenerative Medicine, LLC, Vanderbilt University |
| NCT06162832 | Phase 2 | Jan 10, 2024 | LifeNet Health, Lynch Biologics LLC, Universidad Autonoma de Nuevo Leon, University of Pittsburgh |
| NCT06390124 | Phase 4 | Sep 1, 2022 | COMPLEJO HOSPITALARIO UNIVERSITARIO, BADAJOZ |
| NCT02996760 | Phase 3 | Mar 1, 2017 | IVI Bilbao |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lynch Regenerative Medicine, LLC | Academic/Hospital | 2 | 0 | 1 | 2024 |
| Vanderbilt University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| COMPLEJO HOSPITALARIO UNIVERSITARIO, BADAJOZ | Academic/Hospital | 1 | 1 | 1 | 2022 |
| IVI Bilbao | Academic/Hospital | 1 | 1 | 1 | 2017 |
| LifeNet Health | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Lynch Biologics LLC | For profit | 1 | 0 | 1 | 2024 |
| Universidad Autonoma de Nuevo Leon | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2024 |
8 organizations
Page 1 / 1